To our knowledge this study is the first one showing that in a large randomized trial patient population high B cell-attracting chemokine CXCL13 is independently associated with favorable survival outcomes, indicating an important role of the humoral immune response in disease control among patients with early breast cancer. The gene discussed is CXCL13; the disease is breast cancer.